NEW YORK, April 7, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Johnson & Johnson (NYSE: JNJ), Pfizer Inc. (NYSE: PFE), Merck
& Co., Inc. (NYSE: MRK), GlaxoSmithKline plc (NYSE: GSK), and
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Private wealth
members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
Johnson & Johnson Analyst Notes
On April 1, 2014, Janssen Research
& Development, LLC (Janssen), part of the Janssen
Pharmaceutical Companies of Johnson & Johnson, announced that
it has submitted a New Drug Application (NDA) to the FDA, seeking
approval for a once-daily fixed-dose antiretroviral combination
tablet containing darunavir (PREZISTA) with cobicistat. "Darunavir
is the most prescribed HIV protease inhibitor in the United States1
and we are excited to be taking this important step in our efforts
to offer it with an alternative boosting agent in a fixed-dose
combination tablet," said Johan van
Hoof, M.D., Therapeutic Area Head of Infectious Diseases and
Vaccines at Janssen. "This filing demonstrates our ongoing
commitment to develop new HIV treatment options and fixed-dose
treatment regimens for those living with the disease." The full
analyst notes on Johnson & Johnson are available to download
free of charge at:
http://www.AnalystsReview.com/04072014/JNJ/report.pdf
Pfizer Inc. Analyst Notes
On March 28, 2014, Pfizer Inc.
(Pfizer) announced that the FDA has approved over-the-counter
Nexium 24HR (esomeprazole 20mg). According to the Company, the
approval marks a key step towards providing those who suffer from
frequent heartburn broader access to a brand doctors and patients
have trusted for years. "Switching medicines, whenever appropriate,
from prescription to non-prescription status improves access,
empowers consumers to care for their own health and is an important
strategy for Pfizer," said Paul
Sturman, President of Pfizer Consumer Healthcare. "The FDA
approval of Nexium 24HR is a significant milestone in executing
against our plan." The Company said that it is working closely with
AstraZeneca and retail partners to make Nexium® 24HR available to
consumers in the U.S., and to follow in other markets in
Europe in 2014. The full analyst
notes on Pfizer Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/04072014/PFE/report.pdf
Merck & Co., Inc. Analyst Notes
On March 27, 2014, Merck &
Co., Inc. (Merck) announced the appointment of Robert M. Davis as the Company's Executive Vice
President and CFO, effective April 23,
2014. Succeeding Peter N.
Kellogg, Davis will be responsible for overseeing corporate
strategy and corporate business development. "Rob's broad, global
business and healthcare experience, which encompasses commercial,
R&D, quality, regulatory, manufacturing and supply chain, will
be an asset to us in implementing a significantly streamlined, more
flexible cost structure and operating model, while enabling us to
focus on our highest-potential growth opportunities," said
Kenneth C. Frazier, Chairman and
CEO, Merck. The full analyst notes on Merck & Co., Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04072014/MRK/report.pdf
GlaxoSmithKline plc Analyst Notes
On April 2, 2014, GlaxoSmithKline
plc (GSK) announced its decision to stop the MAGRIT trial, a Phase
III trial of the Company's MAGE-A3 cancer immunotherapeutic in
non-small cell lung cancer (NSCLC) patients. The Company
established that it will not be possible to identify a
sub-population of gene-signature positive NSCLC patients that may
benefit from the treatment, and thereby decided to cease the trial.
"While we are extremely disappointed to learn that this trial did
not have a positive outcome for the patients who participated in
this trial, we are very grateful to its participants. We hope that
the data generated in this trial will advance our understanding of
the science of immunotherapeutics, and ultimately towards
development of new therapies," said Vincent
Brichard, Senior Vice President and Head of
Immunotherapeutics at GSK Vaccines. The full analyst notes on
GlaxoSmithKline plc are available to download free of charge
at:
http://www.AnalystsReview.com/04072014/GSK/report.pdf
Intercept Pharmaceuticals, Inc. Analyst Notes
On April 1, 2014, Intercept
Pharmaceuticals, Inc. (Intercept) announced that it has commenced
an underwritten public offering of 1.0 million shares of its common
stock. The Company informed that 0.6 million of the shares in the
offering are to be sold by Intercept, and 0.4 million are to be
sold by certain institutional selling stockholders. In addition,
the Company informed that the selling stockholders intend to grant
the underwriters a 30-day option to purchase up to an additional
150,000 shares of common stock on the same terms and conditions.
The full analyst notes on Intercept Pharmaceuticals, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04072014/ICPT/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review